(Total Views: 4373)
Posted On: 05/03/2017 1:24:35 PM
Post# of 1460
NTRP back over 10, after the takedown into the 6's.
Looks like people did a little more research on this. I think they did a rotten job of designing the trial, and an even worse job of presenting the data in a way that would be meaningful to the casual investor -- but the drug is still promising.
Looks like people did a little more research on this. I think they did a rotten job of designing the trial, and an even worse job of presenting the data in a way that would be meaningful to the casual investor -- but the drug is still promising.
(0)
(0)
